Date:October 02, 2012

Chrystal Louis, MD, MPH

Crystal Louis, M.D., M.P.H.Assistant Professor
Department of Pediatrics
Section of Hematology-Oncology
Baylor College of Medicine

Dr. Chrystal U. Louis
Texas Children’s Cancer Center
1102 Bates Street, Suite 1570
Houston, TX 77030

832-824-4809
Fax: 832-825-4668
culouis@txch.org

 

About Crystal Louis, MD, MPH

Dr. Louis is a member of the Bone Marrow Transplant (BMT)/Stem Cell Transplant Program.

Her clinical interests include bone marrow transplantation, solid tumors, rare cancers, and renal function in pediatric patients with cancer or blood disorders.

Research

Dr. Chrystal Louis is a member of the translational research laboratory in the Center for Cell and Gene Therapy (CAGT). Her research interests include: 1) Immunotherapy improvement options and 2) Therapeutic strategies for patients with nasopharyngeal carcinoma (NPC) or neuroblastoma.

In association with Dr. Stephen Gottschalk and Dr. Helen Heslop, she has been working on methods to improve immunotherapy options for patients with solid tumors. At this time, she has focused her research on therapeutic strategies for patients with either nasopharyngeal carcinoma (NPC) or neuroblastoma. Most cases of advanced-stage NPC are associated with Epstein Barr virus (EBV), and our center previously determined that administration of adoptively transferred EBV-specific cytotoxic T lymphocytes (EBV-CTL) was safe and produced anti-tumor effects in 50% of patients. Therefore, Dr. Chrystal Louis’ current research efforts have focused on improving the specificity of the CTL product for NPC tumors and identifying additional, non-EBV associated tumor markers that can also be used as immunotherapy targets.

For patients with high-risk neuroblastoma, prior studies have shown clinical responses after active immunization; however, responses were limited by the poorly immunogenic nature of neuroblastoma tumor-cell vaccines. Dr. Chrystal Louis and colleagues are now investigating the safety, immune response, and anti-tumor activity of more potent, genetically modified neuroblastoma tumor cell vaccines after high-dose chemotherapy and stem cell rescue. Additionally, the group is continuing their study using adoptively transferred T cells modified to express receptors for GD2 in patients with a history of high-risk neuroblastoma.

Education

MD, Tulane University School of Medicine
MPH, Tulane University School of Public Health and Tropical Medicine
Residency, University of California at Davis
Fellowship, Baylor College of Medicine

Board Certifications

American Board of Pediatrics
American Board of Pediatrics – Hematology/Oncology

Selected Memberships

Member, American Association of Cancer Research (AACR)
Member, American Society of Bone Marrow Transplantation (ASBMT)
Member, American Society of Clinical Oncology (ASCO)
Member, American Society of Pediatric Hematology and Oncology (ASPHO)